STOCKS NEWS EUROPE-BTG jumps on FDA nod for embolism treatment

Shares in BTG Plc (Other OTC: BTGGF - news) climb 8.5 percent to the top Britain's FTSE-250 midcap index after the British pharmaceutical firm says its device used to treat pulmonary embolism has won clearance from the U.S. FDA.

The U.S. Food and Drug Administration (FDA) has cleared EkoSonic Endovascular System - a minimally invasive endovascular therapy - as a treatment for pulmonary embolisms, the drug developer says in a statement on Friday.

Pulmonary embolism occurs in about 600,000 patients in the United States, causing or contributing to 15 percent of all hospital deaths, research quoted by BTG shows.

"An upgrading opportunity has presented itself today with the approval of EkoSonic for the treatment of pulmonary embolism," Panmure Gordon and Co analyst Savvas Neophytou, who has a "buy" rating on the stock, says.

For more, click on

To see BTG's statement, click on

Reuters messaging rm://esha.vaish.thomsonreuters.com@reuters.net